Aberrant function of myeloid-derived suppressor cells (MDSCs) in experimental colitis and in inflammatory bowel disease (IBD) immune responses. (3rd April 2017)
- Record Type:
- Journal Article
- Title:
- Aberrant function of myeloid-derived suppressor cells (MDSCs) in experimental colitis and in inflammatory bowel disease (IBD) immune responses. (3rd April 2017)
- Main Title:
- Aberrant function of myeloid-derived suppressor cells (MDSCs) in experimental colitis and in inflammatory bowel disease (IBD) immune responses
- Authors:
- Kontaki, Eleni
Boumpas, Dimitrios T.
Tzardi, Maria
Mouzas, Ioannis A.
Papadakis, Konstantinos A.
Verginis, Panayotis - Abstract:
- Abstract: Background and aims : Myeloid-derived suppressor cells (MDSCs) encompass a novel population of suppressor cells and a potential candidate for cell-based therapies in inflammatory diseases. Herein, we investigated their immunomodulatory properties in experimental inflammatory colitis and T cell-mediated immune responses in inflammatory bowel disease (IBD) patients. Methods : MDSCs (defined as CD14 − HLA − DR −/low CD33 + CD15 + ) numbers were determined in peripheral blood (PB) from IBD patients. PB MDSC function was assessed in vitro . Experimental colitis was induced upon 2, 4, 6-trinitrobenzene sulfonic acid (TNBS) treatment and MDSCs were characterized by flow cytometry. The in vivo suppressive potential of bone marrow (BM)-derived MDSCs (BM-MDSCs) was tested by using both depleting and adoptive transfer strategies. Results : MDSCs were enriched in the periphery of IBD patients during active disease. TNBS colitis induced amplification of MDSCs, particularly of the granulocytic (Ly6G + ) subset during the effector phase of disease. Of interest, BM-MDSCs potently suppressed CD4 + T cell responses under steady state but failed to control colitis-associated immune responses in vivo . Mechanistically, under the colonic inflammatory milieu MDSCs switched phenotype (decreased proportion of Gr1 high and increased numbers of Gr1 low ) and downregulated CCAAT/enhancer-binding protein beta (CEBPβ) expression, a critical transcription factor for the suppressive function ofAbstract: Background and aims : Myeloid-derived suppressor cells (MDSCs) encompass a novel population of suppressor cells and a potential candidate for cell-based therapies in inflammatory diseases. Herein, we investigated their immunomodulatory properties in experimental inflammatory colitis and T cell-mediated immune responses in inflammatory bowel disease (IBD) patients. Methods : MDSCs (defined as CD14 − HLA − DR −/low CD33 + CD15 + ) numbers were determined in peripheral blood (PB) from IBD patients. PB MDSC function was assessed in vitro . Experimental colitis was induced upon 2, 4, 6-trinitrobenzene sulfonic acid (TNBS) treatment and MDSCs were characterized by flow cytometry. The in vivo suppressive potential of bone marrow (BM)-derived MDSCs (BM-MDSCs) was tested by using both depleting and adoptive transfer strategies. Results : MDSCs were enriched in the periphery of IBD patients during active disease. TNBS colitis induced amplification of MDSCs, particularly of the granulocytic (Ly6G + ) subset during the effector phase of disease. Of interest, BM-MDSCs potently suppressed CD4 + T cell responses under steady state but failed to control colitis-associated immune responses in vivo . Mechanistically, under the colonic inflammatory milieu MDSCs switched phenotype (decreased proportion of Gr1 high and increased numbers of Gr1 low ) and downregulated CCAAT/enhancer-binding protein beta (CEBPβ) expression, a critical transcription factor for the suppressive function of MDSCs. In accordance with the murine data, human CD33 + CD15 + MDSCs from peripheral blood of IBD patients not only failed to suppress autologous T cell responses but instead enhanced T cell proliferation in vitro. Conclusions : Our findings demonstrate an aberrant function of MDSCs in experimental inflammatory colitis and in IBD-associated immune responses in vitro . Delineation of the mechanisms that underlie the loss of MDSCs function in IBD may provide novel therapeutic targets. … (more)
- Is Part Of:
- Autoimmunity. Volume 50:Number 3(2017)
- Journal:
- Autoimmunity
- Issue:
- Volume 50:Number 3(2017)
- Issue Display:
- Volume 50, Issue 3 (2017)
- Year:
- 2017
- Volume:
- 50
- Issue:
- 3
- Issue Sort Value:
- 2017-0050-0003-0000
- Page Start:
- 170
- Page End:
- 181
- Publication Date:
- 2017-04-03
- Subjects:
- MDSCs -- BM-MDSCs -- IBD -- experimental colitis -- CEBPβ
Autoimmunity -- Periodicals
Autoimmune diseases -- Periodicals
571.973 - Journal URLs:
- http://informahealthcare.com/journal/aut ↗
http://informahealthcare.com ↗
http://www.gbhap.com/journals/350/350-top.htm ↗ - DOI:
- 10.1080/08916934.2017.1283405 ↗
- Languages:
- English
- ISSNs:
- 0891-6934
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 1828.345000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 991.xml